BioWorld Science

April 14, 2005

View Archived Issues

5-HT1A receptor stimulation reduces damage after cerebral infarction

Read More

GSK-3beta: a therapeutic target for pancreatic cancer

Read More

NeuGene antisense technology validation for dengue fever and West Nile virus

Read More

West Nile virus recombinant DNA plasmid vaccine moves into phase I studies / News in Context

Read More

Phase III PolyHeme study cleared to continue

Read More

DiObex licenses rights to cortisol inhibitors from Cortendo

Read More

Trigen and ProCorde merge

Read More

Reminyl renamed Razadyne

Read More

Approval for Femara in Canada

Read More

Perlegen licenses PPAR agonist from Mitsubishi Pharma

Read More

GCAN-101 under evaluation in phase II study

Read More

European phase II study of SPI-153 for hormone-dependent prostate cancer

Read More

Approvable letter for Ambien CR

Read More

Ferring launches Menopur

Read More

AM-Pharma receives subsidy for development of hLF1-11

Read More

FDA requests boxed warnings on atypical antipsychotics

Read More

GTI-2040 combination therapy completes phase II trial in kidney cancer

Read More

Ocaperidone reported effective in schizophrenia

Read More

New data on the antiepileptic efficacy of lacosamide

Read More

Sodium valproate reported to induce no changes in the PK profile of talampanel

Read More

Low dopamine receptor availability found in patients with mTLE

Read More

Pharmexa to acquire GemVax

Read More

New treatments claimed for allergic reactions and respiratory diseases

Read More

New class of inhibitors of HBsAg secretion described

Read More

New treatment for hot flushes in prostate cancer patients claimed by Boehringer Ingelheim

Read More

Naphthalene derivative identified as HIV-1 inhibitor

Read More

New sodium channel blockers emerge from Ionix R&D

Read More

Farnesyltransferase inhibitors tipifarnib, BMS-214662 evaluated in phase I studies

Read More